At least grade 3 adverse events occurring in 2 or more patients
| . | n (%) . | N (%) . | |||||
|---|---|---|---|---|---|---|---|
| AITL, n = 13 . | PTCL-NOS, n = 22 . | Overall total, N = 35 . | |||||
| Grade . | 3 . | 4 . | 5 . | 3 . | 4 . | 5 . | ≥3 . |
| Neutropenia | 2 (15) | 0 | 0 | 3 (14) | 0 | 0 | 5 (14) |
| Hyperkalemia | 0 | 1 (8) | 0 | 2 (9) | 0 | 0 | 3 (9) |
| Peripheral sensory neuropathy | 3 (23) | 0 | 0 | 0 | 0 | 0 | 3 (9) |
| Acute renal failure | 0 | 0 | 0 | 2 (9) | 0 | 0 | 2 (6) |
| Anemia | 1 (8) | 0 | 0 | 1 (5) | 0 | 0 | 2 (6) |
| Dehydration | 0 | 0 | 0 | 2 (9) | 0 | 0 | 2 (6) |
| Disease progression | 0 | 0 | 1 (8) | 1 (5) | 0 | 0 | 2 (6) |
| Pneumonia | 0 | 1 (8) | 0 | 1 (5) | 0 | 0 | 2 (6) |
| Thrombocytopenia | 0 | 0 | 0 | 2 (9) | 0 | 0 | 2 (6) |
| Tumor lysis syndrome | 0 | 0 | 0 | 2 (9) | 0 | 0 | 2 (6) |
| Urinary tract infection | 1 (8) | 0 | 0 | 1 (5) | 0 | 0 | 2 (6) |
| . | n (%) . | N (%) . | |||||
|---|---|---|---|---|---|---|---|
| AITL, n = 13 . | PTCL-NOS, n = 22 . | Overall total, N = 35 . | |||||
| Grade . | 3 . | 4 . | 5 . | 3 . | 4 . | 5 . | ≥3 . |
| Neutropenia | 2 (15) | 0 | 0 | 3 (14) | 0 | 0 | 5 (14) |
| Hyperkalemia | 0 | 1 (8) | 0 | 2 (9) | 0 | 0 | 3 (9) |
| Peripheral sensory neuropathy | 3 (23) | 0 | 0 | 0 | 0 | 0 | 3 (9) |
| Acute renal failure | 0 | 0 | 0 | 2 (9) | 0 | 0 | 2 (6) |
| Anemia | 1 (8) | 0 | 0 | 1 (5) | 0 | 0 | 2 (6) |
| Dehydration | 0 | 0 | 0 | 2 (9) | 0 | 0 | 2 (6) |
| Disease progression | 0 | 0 | 1 (8) | 1 (5) | 0 | 0 | 2 (6) |
| Pneumonia | 0 | 1 (8) | 0 | 1 (5) | 0 | 0 | 2 (6) |
| Thrombocytopenia | 0 | 0 | 0 | 2 (9) | 0 | 0 | 2 (6) |
| Tumor lysis syndrome | 0 | 0 | 0 | 2 (9) | 0 | 0 | 2 (6) |
| Urinary tract infection | 1 (8) | 0 | 0 | 1 (5) | 0 | 0 | 2 (6) |